Milestone Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview

Milestone Pharmaceuticals

08/05/2023 18:22

* Milestone Pharmaceuticals Inc  MIST.OQ   MIST.O  is
expected
to show no change in quarterly revenue when it reports 
results on May 10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Milestone
Pharmaceuticals
Inc is for a loss of 40 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Milestone
Pharmaceuticals Inc is $13​, above​ its last closing price
of $3.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.33      -0.31     Beat    7.5
 Sep. 30 2022  -0.40       -0.41      -0.34     Beat    16.7
 Jun. 30 2022  -0.34       -0.36      -0.39     Missed  -8.3​
 Mar. 31 2022  -0.38       -0.39      -0.33     Beat    15.4
 ​​Dec.                    -0.36      -0.40     Missed  -9.9
 31 2021                                                
 Sep. 30 2021  -0.40       -0.38      -0.34     Beat    11.5​
 Jun. 30 2021  -0.27       -0.26      0.02      Beat    107.6
 Mar. 31 2021  -0.32       -0.33      -0.30     Beat    8.5
 This summary was machine generated May 8 at 17:22 GMT.  All
figures in US dollars  unless otherwise stated